Cingulate Completes Pre-NDA Meeting with FDA for CTX-1301
Cingulate Inc. held a Pre-NDA meeting with the FDA to discuss its new drug application for CTx-1301, a treatment...
Pacira Initiates Phase 2 Osteoarthritis Knee Study
Pacira BioSciences has initiated a Phase 2 clinical trial, ASCEND, for PCRX-201, a locally administered gene therapy designed to...
Neurona Therapeutics Raises $102M for Epilepsy Cell Therapy Trial
Neurona Therapeutics secured $102 million in an oversubscribed financing round, fueled by positive clinical data from its ongoing Phase...
Coaptium Connect System’s Clinical Results for Nerve Repair
TISSIUM’s COAPTIUM® CONNECT System, a novel sutureless solution for peripheral nerve repair, has shown promising results in a clinical...
Alpha Tau FDA Clearance for Recurrent Glioblastoma Trial
Alpha Tau Medical (NASDAQ: DRTS, DRTSW) received FDA clearance for an Investigational Device Exemption (IDE) to begin a pilot...
FibroBiologics Announces Breakthrough Brain Tissue Repair Results
FibroBiologics, a clinical-stage biotech company, announced positive results from a preclinical study investigating the use of intravenous fibroblasts to...
Johns Hopkins Doses Nasal Foralumab in MS Trial
Tiziana Life SciencesLife Sciences has initiated dosing at Johns Hopkins University, the third site in its Phase 2 trial...
Acumen’s P-tau217 Trial Shows Progress in Phase 2 & Preclinical Research
Acumen Pharmaceuticals presented extended results from its plasma pTau217 assay used to screen participants in the Phase 2 ALTITUDE-AD...
Neflamapimod Shows Promise in Slowing Dementia with Lewy Bodies Progression
CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia...
Enormous Parkinson’s Breakthrough: Phase 2 Trial Shows Positive Results
AC Immune announced positive interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein (a-syn) in early...